Mickaël Aoun

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Johan Maertens, Issam Raad, Kieren A. Marr et al. · The Lancet · 2015 · 972 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Alemnew F. Dagnew, Osman İlhan, Won Sik Lee et al. · The Lancet Infectious Diseases · 2019 · 254 citations · Full text

Veterinary Medicine, Immunology, Oncology +16

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study

Johan Maertens, George R. Thompson, Andrej Spec et al. · The Lancet Infectious Diseases · 2025 · 62 citations · Full text

Pharmacy, Microbiology, Pharmacotherapy +13

Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer

Johan Maertens, Tom Lodewyck, J. Peter Donnelly et al. · Clinical Infectious Diseases · 2022 · 61 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation

Imran Ahmad, Nguyen Van Cau, John Kwan et al. · Transplantation · 2009 · 59 citations

Life Sciences, Hematology, Immunology +14